The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Dec 19, 2023 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Sell(S) | 29K | $0.08 | $2K |
| Dec 19, 2023 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Sell(S) | 209K | $0.08 | $17K |
| Dec 18, 2023 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Sell(S) | 209K | $0.11 | $23K |
| Dec 18, 2023 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Sell(S) | 29K | $0.11 | $3K |
| Dec 15, 2023 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Sell(S) | 12K | $0.29 | $3K |
| Dec 15, 2023 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Sell(S) | 88K | $0.29 | $26K |
| Nov 30, 2023 | Oaktree Specialty Lending Corp | 10% Owner | Other(J) | 445K | — | — |
| Nov 30, 2023 | Oaktree AZ Strategic Lending Fund, L.P. | 10% Owner | Other(J) | 445K | — | — |
| Nov 30, 2023 | BROOKFIELD Corp | 10% Owner | Other(J) | 445K | — | — |
| Jun 16, 2023 | Allison David D. | Director | Grant(A) | 13K | — | $0 |
| Jun 16, 2023 | Nelson Timothy S | Director | Grant(A) | 13K | — | $0 |
| Jun 16, 2023 | Shah Mahendra | Director | Grant(A) | 13K | — | $0 |
| Jun 16, 2023 | Wilfong Diane E. | Director | Grant(A) | 13K | — | $0 |
| Jun 16, 2023 | Cline Darren S | Director | Grant(A) | 13K | — | $0 |
| May 10, 2023 | Kalb Michael Wayne | CFO | Grant(A) | 48K | — | $0 |
| May 10, 2023 | Kalb Michael Wayne | CFO | Grant(A) | 175K | — | $0 |
| Apr 12, 2023 | Cline Darren S | Director | Grant(A) | 20K | — | $0 |
| Feb 14, 2023 | Adams Adrian | COB, CEO and President, Director | Grant(A) | 200K | — | $0 |
| Feb 14, 2023 | Leaman John Harold | Chief Fin. & Business Officer | Grant(A) | 70K | — | $0 |
| Feb 14, 2023 | Hoekman John | Chief Scientific Officer | Grant(A) | 43K | — | $0 |
| Feb 14, 2023 | Paolillo Leonard | Chief Commercial Officer | Grant(A) | 50K | — | $0 |
| Dec 31, 2022 | Leaman John Harold | Chief Fin. & Business Officer | Option exercise(M) | 11K | — | $0 |
| Dec 31, 2022 | Leaman John Harold | Chief Fin. & Business Officer | Tax withholding(F) | 4K | $3.75 | $14K |
| Dec 31, 2022 | Leaman John Harold | Chief Fin. & Business Officer | Option exercise(M) | 11K | — | $0 |
| Jun 16, 2022 | Allison David D. | Director | Grant(A) | 13K | — | $0 |
| Jun 16, 2022 | Parker H Stewart | Director | Grant(A) | 13K | — | $0 |
| Jun 16, 2022 | Nelson Timothy S | Director | Grant(A) | 13K | — | $0 |
| Jun 16, 2022 | Shah Mahendra | Director | Grant(A) | 13K | — | $0 |
| Jun 16, 2022 | Wilfong Diane E. | Director | Grant(A) | 13K | — | $0 |
| Mar 29, 2022 | Shrewsbury Stephen B | Chief Medical Officer | Option exercise(M) | 25K | $1.97 | $48K |
| Mar 29, 2022 | Shrewsbury Stephen B | Chief Medical Officer | Option exercise(M) | 25K | — | $0 |
| Jan 26, 2022 | Adams Adrian | COB, CEO and President, Director | Grant(A) | 175K | — | $0 |
| Jan 26, 2022 | Hoekman John | Chief Scientific Officer | Grant(A) | 35K | — | $0 |
| Jan 26, 2022 | Leaman John Harold | Chief Fin. & Business Officer | Grant(A) | 100K | — | $0 |
| Jan 26, 2022 | Paolillo Leonard | Chief Commercial Officer | Grant(A) | 40K | — | $0 |
| Jan 26, 2022 | Shrewsbury Stephen B | Chief Medical Officer | Grant(A) | 30K | — | $0 |
| Dec 22, 2021 | Hoekman John | Chief Scientific Officer | Option exercise(M) | 20K | $1.64 | $33K |
| Dec 22, 2021 | Hoekman John | Chief Scientific Officer | Option exercise(M) | 20K | — | $0 |
| Nov 19, 2021 | Nelson Timothy S | Director | Buy(P) | 10K | $10.76 | $108K |
| Oct 19, 2021 | Leaman John Harold | Chief Fin. & Business Officer | Grant(A) | 11K | — | $0 |
| Sep 21, 2021 | Shrewsbury Stephen B | Chief Medical Officer | Option exercise(M) | 54K | $2.95 | $159K |
| Sep 21, 2021 | Shrewsbury Stephen B | Chief Medical Officer | Option exercise(M) | 5K | $2.46 | $11K |
| Sep 21, 2021 | Shrewsbury Stephen B | Chief Medical Officer | Option exercise(M) | 15K | $1.97 | $29K |
| Sep 21, 2021 | Shrewsbury Stephen B | Chief Medical Officer | Option exercise(M) | 54K | — | $0 |
| Sep 21, 2021 | Shrewsbury Stephen B | Chief Medical Officer | Option exercise(M) | 5K | — | $0 |
| Sep 21, 2021 | Shrewsbury Stephen B | Chief Medical Officer | Option exercise(M) | 15K | — | $0 |
| Aug 18, 2021 | Adams Adrian | COB, CEO and President, Director | Buy(P) | 17K | $13.81 | $238K |
| Aug 18, 2021 | Adams Adrian | COB, CEO and President, Director | Buy(P) | 2K | $14.91 | $33K |
| Aug 18, 2021 | Adams Adrian | COB, CEO and President, Director | Buy(P) | 600 | $15.89 | $10K |
| Jul 20, 2021 | Adams Adrian | COB, CEO and President, Director | Grant(A) | 50K | — | $0 |
| Jul 20, 2021 | Hoekman John | Chief Scientific Officer | Grant(A) | 50K | — | $0 |
| Jul 20, 2021 | Leaman John Harold | Chief Financial Officer | Grant(A) | 50K | — | $0 |
| Jul 20, 2021 | Paolillo Leonard | Chief Commercial Officer | Grant(A) | 30K | — | $0 |
| Jul 20, 2021 | Shrewsbury Stephen B | Chief Medical Officer | Grant(A) | 50K | — | $0 |
| Jul 11, 2021 | Allison David D. | Director | Grant(A) | 12K | — | $0 |
| Jul 11, 2021 | Nelson Timothy S | Director | Grant(A) | 12K | — | $0 |
| Jul 11, 2021 | Parker H Stewart | Director | Grant(A) | 12K | — | $0 |
| Jul 11, 2021 | Shah Mahendra | Director | Grant(A) | 12K | — | $0 |
| Jul 11, 2021 | Wilfong Diane E. | Director | Grant(A) | 12K | — | $0 |
| Apr 27, 2021 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Conversion(C) | 11.6M | — | $0 |
| Apr 27, 2021 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Conversion(C) | 5.2M | — | $0 |
| Apr 27, 2021 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Conversion(C) | 996K | — | $0 |
| Apr 27, 2021 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Conversion(C) | 7.2M | — | $0 |
| Apr 27, 2021 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Conversion(C) | 713K | — | $0 |
| Apr 27, 2021 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Conversion(C) | 0 | — | $0 |
| Apr 27, 2021 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Conversion(C) | 0 | — | $0 |
| Apr 27, 2021 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Conversion(C) | 1.1M | — | $0 |
| Apr 27, 2021 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Conversion(C) | 7.8M | — | $0 |
| Apr 27, 2021 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Conversion(C) | 1.6M | — | $0 |
| Apr 27, 2021 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Buy(P) | 69K | $15.00 | $1.0M |
| Apr 27, 2021 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Buy(P) | 506K | $15.00 | $7.6M |
| Apr 27, 2021 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Conversion(C) | 12K | $13.50 | $166K |
| Apr 27, 2021 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Conversion(C) | 89K | $13.50 | $1.2M |
| Apr 27, 2021 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Conversion(C) | 44K | — | — |
| Apr 27, 2021 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Conversion(C) | 315K | — | — |
| Apr 27, 2021 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Conversion(C) | 61K | — | — |
| Apr 27, 2021 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Conversion(C) | 440K | — | — |
| Apr 27, 2021 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Conversion(C) | 66K | — | — |
| Apr 27, 2021 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Conversion(C) | 475K | — | — |
| Apr 27, 2021 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Conversion(C) | 98K | — | — |
| Apr 27, 2021 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Conversion(C) | 710K | — | — |
| Apr 27, 2021 | venBio Global Strategic Fund II L.P. | 10% Owner | Buy(P) | 450K | $15.00 | $6.8M |
| Apr 27, 2021 | venBio Global Strategic Fund II L.P. | 10% Owner | Conversion(C) | 2.3M | — | — |
| Apr 27, 2021 | venBio Global Strategic Fund II L.P. | 10% Owner | Conversion(C) | 5.9M | — | $0 |
| Apr 27, 2021 | venBio Global Strategic Fund II L.P. | 10% Owner | Conversion(C) | 0 | — | $0 |
| Apr 27, 2021 | venBio Global Strategic Fund II L.P. | 10% Owner | Conversion(C) | 13.2M | — | $0 |
| Apr 27, 2021 | venBio Global Strategic Fund II L.P. | 10% Owner | Conversion(C) | 8.2M | — | $0 |
| Apr 27, 2021 | venBio Global Strategic Fund II L.P. | 10% Owner | Conversion(C) | 8.8M | — | $0 |
| Apr 27, 2021 | Kravis Henry R | 10% Owner | Other(J) | 119K | $13.50 | $1.6M |
| Apr 27, 2021 | Kravis Henry R | 10% Owner | Conversion(C) | 2.6M | — | — |
| Apr 27, 2021 | Kravis Henry R | 10% Owner | Buy(P) | 1.1M | $15.00 | $16.5M |
| Apr 27, 2021 | Kravis Henry R | 10% Owner | Conversion(C) | 42.3M | — | — |
| Apr 27, 2021 | Parker H Stewart | Director | Conversion(C) | 4K | — | — |
| Apr 27, 2021 | Parker H Stewart | Director | Conversion(C) | 7K | — | — |
| Apr 27, 2021 | Parker H Stewart | Director | Other(J) | 458 | — | $0 |
| Apr 27, 2021 | Parker H Stewart | Director | Conversion(C) | 9K | — | — |
| Apr 27, 2021 | Parker H Stewart | Director | Conversion(C) | 271 | $13.50 | $4K |
| Apr 27, 2021 | Parker H Stewart | Director | Other(J) | 2K | — | $0 |
| Apr 27, 2021 | Parker H Stewart | Director | Conversion(C) | 61K | — | $0 |
| Apr 27, 2021 | Parker H Stewart | Director | Option exercise(X) | 14K | $8.19 | $113K |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2021-03-29 → 2026-07-14. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).